Published in Curr Pharm Des on January 01, 2007
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res (2010) 1.96
Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev (2009) 1.76
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene (2010) 1.70
The role of IGF-1R in pediatric malignancies. Oncologist (2009) 1.27
Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways. Mutat Res (2008) 1.18
Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res (2013) 1.12
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem (2009) 1.10
Insulin and insulin-like growth factor II differentially regulate endocytic sorting and stability of insulin receptor isoform A. J Biol Chem (2012) 1.09
Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation. Cell Mol Life Sci (2013) 1.08
Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am (2012) 1.07
Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer. J Oncol (2010) 1.06
Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. PLoS One (2012) 1.00
The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) (2011) 0.99
ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Mol Cancer Ther (2013) 0.96
Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma (2011) 0.96
Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res (2011) 0.91
Insulin-like growth factor 1-mediated hyperthermia involves anterior hypothalamic insulin receptors. J Biol Chem (2011) 0.91
Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? J Clin Oncol (2011) 0.90
Decorin differentially modulates the activity of insulin receptor isoform A ligands. Matrix Biol (2014) 0.88
Subsets of very low risk Wilms tumor show distinctive gene expression, histologic, and clinical features. Clin Cancer Res (2009) 0.88
Oncogenic functions of IGF1R and INSR in prostate cancer include enhanced tumor growth, cell migration and angiogenesis. Oncotarget (2014) 0.88
Targeting the IGF-1R: The Tale of the Tortoise and the Hare. Front Endocrinol (Lausanne) (2015) 0.87
Insulin-like growth factor-1 receptor-targeted therapy for non-small cell lung cancer: a mini review. Am J Transl Res (2009) 0.87
Ligand-mediated endocytosis and trafficking of the insulin-like growth factor receptor I and insulin receptor modulate receptor function. Front Endocrinol (Lausanne) (2014) 0.85
World congress on insulin resistance, diabetes, and cardiovascular disease: Part 1. Diabetes Care (2011) 0.85
Differential expression and signaling activation of insulin receptor isoforms A and B: A link between breast cancer and diabetes. Growth Factors (2011) 0.84
Insulin-like growth factor system in cancer: novel targeted therapies. Biomed Res Int (2015) 0.84
C57BL/KsJ-db/db-Apc mice exhibit an increased incidence of intestinal neoplasms. Int J Mol Sci (2011) 0.83
Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology (2011) 0.82
Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One (2013) 0.81
Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell lines. PLoS One (2012) 0.81
Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. Front Endocrinol (Lausanne) (2015) 0.81
The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy. Br J Clin Pharmacol (2014) 0.80
Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. Br J Cancer (2014) 0.80
The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link. Front Endocrinol (Lausanne) (2015) 0.80
The insulin and igf-I pathway in endocrine glands carcinogenesis. J Oncol (2012) 0.80
Will targeting insulin growth factor help us or hurt us?: An oncologist's perspective. Ageing Res Rev (2009) 0.79
Novel cross talk between IGF-IR and DDR1 regulates IGF-IR trafficking, signaling and biological responses. Oncotarget (2015) 0.79
Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cells. PLoS One (2012) 0.79
The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). J Transl Med (2010) 0.78
Novel roles for insulin receptor (IR) in adipocytes and skeletal muscle cells via new and unexpected substrates. Cell Mol Life Sci (2012) 0.78
Targeting Insulin Receptor with a Novel Internalizing Aptamer. Mol Ther Nucleic Acids (2016) 0.78
Modulation of insulin/IGFs pathways by sirtuin-7 inhibition in drug-induced chemoreistance. Diagn Pathol (2014) 0.77
Theoretical and computational studies of peptides and receptors of the insulin family. Membranes (Basel) (2015) 0.77
A Drosophila Model of HPV E6-Induced Malignancy Reveals Essential Roles for Magi and the Insulin Receptor. PLoS Pathog (2016) 0.77
Metformin effects on biochemical recurrence and metabolic signaling in the prostate. Prostate (2015) 0.76
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer (2016) 0.75
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Front Endocrinol (Lausanne) (2017) 0.75
The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential. Oncotarget (2016) 0.75
Pro-angiogenic Role of Insulin: From Physiology to Pathology. Front Physiol (2017) 0.75
Serum Insulin, Glucose, Indices of Insulin Resistance, and Risk of Lung Cancer. Cancer Epidemiol Biomarkers Prev (2017) 0.75